Drug details

Tadliq (tadalafil oral suspension)

type of Phosphodiesterase-5 Enzyme Inhibitors

Tadliq (tadalafil) is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability.

This drug may have the following side effects:

• nausea,
• headache,
• flushing,
• runny or stuffy nose,
• pain in extremities,
• muscle pain,
• back pain, and
• respiratory tract infection (upper and lower),
• indigestion/heartburn.

The following drugs are related to Tadliq, either as a replacement or used together:

• Adcirca (tadalafil tablets)
• Tracleer (bosentan)
• Veletri (epoprostenol powder for intravenous administration)
• Flolan (epoprostenol sodium)
• Ventavis (iloprost)
• Remodulin (treprostinil sodium)
• Revatio (sildenafil citrate)
• Tyvaso DPI (treprostinil inhalation powder)
• Tyvaso (treprostinil inhalation solution)